definiens: has the meaning set out in Clause 2.7 ; has the meaning set out in Clause 2.8 ; has the meaning set out in Clause 2.7 ; means Lrverco ’s rights under Clause 2.7 and 2.8 ; any Patent Rights filed by or on behalf of UCLB from time to time in respect of ( i ) any work undertaken by AN and/or the AN Laboratory prior to, on or after the Effective Date under or pursuant to the Second Serotype Program as set out in Schedule 1 ; and ( ii ) any Program Know -How identified in ( ii ) of Second Serotype Program IP means, excluding any Additional Royalty Product, any AAV directed gene therapy product which is covered by, uses in its manufacture or incorporates in it a ny of the Second Serotype Program IP licensed to Liverco hereunder ; means the program of research relating to novel AAV serotypes generated, developed or used by AN and/or the AN Laboratory for liver directed AAV therapy, defined in Schedule 1 under the title Second Serotype Program conducted prior to the Effective Date together with the program of research conducted after the Effective Date as described in Schedule 1 under the title Part B : Second Serotype Project Plan ; means ( i ) Second Serotype Patent Rights ; and ( ii ) Program Know -How existing at the date of exercise of the Second Serotype Option applicable to the serotypes isolated from, and/or designed and/or made as part of the Second Serotype Pro gram or Covered by any of the Second Serotype Patent Rights, and their Exploitation thereto ; means the First Serotype Program IP and, where the Second Serotype Option is exercised, the Second Serotype Program IP ; means, e xcluding any Additional Royalty Product, any AAV directed gene therapy product which is covered by, uses in its manufacture or incorporates in it any of the Serotype IP licensed to Liverco hereunder ; has the meaning set out in Clause 15.8 ; means the Subscription and Shareholders ’ Agreement between Liverco, UCLB, Prof. Amit Nathwani, and [ * * ] dated as of the Effective Date ; 20 Certain confidential information contained in this document, marked by [ * * ], has been omitted because the inf ormation ( i ) is not material and ( ii ) would likely cause competitive harm to the Company if publicly disclosed